Controlled release of the fibronectin central cell binding domain from polymeric microspheres.

Non-ionic surfactants have been employed as alternatives to PVA for the emulsification-encapsulation of a conformationally labile protein (FIII9'-10) into PLGA microspheres. FIII9'-10 was encapsulated using a w/o/w double emulsification-evaporation technique and the microspheres fabricated were characterized by SEM and CLSM. The peptide backbone integrity of FIII9'-10 was assayed by SDS-PAGE and the degree of unfolding of FIII9'-10 following emulsification-encapsulation was assessed using a fibroblast cell-attachment assay. The encapsulation efficiency for FIII9'-10 was 25% when using PVA, compared to 50-60% when using Igepal CA-630 or Triton-X100, with values below for the other surfactants. FIII9'-10 released from microspheres promoted cell attachment in a concentration-dependent manner, only Igepal CA-630 and Triton X-100 maintaining near-maximal cell attachment, indicating that the conformation of the relatively unstable FIII9' domain was preserved. All non-ionic surfactants reduced microsphere surface porosity, compared to PVA, and an increasing surface rugosity (leading to minor 'ridges') could be correlated with decreasing surfactant HLB. Low surface porosities did not effect the diffusion of FIII9'-10 from the microspheres' internal pores in a 'burst release', as may have been imagined. In summary, non-ionic surfactants should be considered over PVA for the maintenance of biological activity of conformationally labile proteins during encapsulation.     

Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone.

A new approach for attaining sustained release of protein is introduced, involving a pore-closing process of preformed porous PLGA microspheres. Highly porous biodegradable poly(D,L-lactic-co-glycolic acid) (PLGA) microspheres were fabricated by a single water-in-oil emulsion solvent evaporation technique using Pluronic F127 as an extractable porogen. Recombinant human growth hormone (rhGH) was incorporated into porous microspheres by a simple solution dipping method. For their controlled release, porous microspheres containing hGH were treated with water-miscible solvents in aqueous phase for production of pore-closed microspheres. These microspheres showed sustained release patterns over an extended period; however, the drug loading efficiency was extremely low. To overcome the drug loading problem, the pore-closing process was performed in an ethanol vapor phase using a fluidized bed reactor. The resultant pore-closed microspheres exhibited high protein loading amount as well as sustained rhGH release profiles. Also, the released rhGH exhibited structural integrity after the treatment.     

A model of dissolution-controlled,diffusional drug release from non-swellable polymeric microspheres

A new model was developed to account for the kinetics of drug release from porous, non-swellable polymeric microparticles in the case where both drug dissolution and diffusion mechanisms control the overall release process. The model incorporates a linear first-order dissolution term and the transient Fickian diffusion equation, and is solved for perfect sink and surface-dependent boundary conditions. Long-term limiting solutions indicate that after an initial time-dependent period of release, the release rate becomes independent of time. Numerical solutions are provided which indicate the effects of particle size, solute diffusion coefficient and solute dissolution rate on the release kinetics.     

Acid-cleavable polymeric core-shell particles for delivery of hydrophobic drugs.

Here we describe the combined use of acid-labile microgel approach and RAFT-mediated seeded dispersion polymerization technique to prepare an acid-cleavable core-shell like polymeric colloidal system for the delivery of hydrophobic drugs at slightly acidic sites. A new bisacrylate acetal crosslinker was copolymerized with n-butyl acrylate (BA) in the presence of a RAFT agent using a dispersion polymerization technique, which yielded crosslinked spherical particles with the size ranging between 150 and 500 nm. The particles were cleaved in a pH-dependent manner similar to the acid-labile hydrolysis behaviour of the crosslinker. In order to mask the hydrophobic surface of the particles, polyethylene glycol acrylate (PEG-A) was grafted onto poly(BA) seed particles via the RAFT agent groups on the particle surface. The acidic-site selective delivery potential of the poly(BA)-g-poly(PEG-A) particles was assessed in-vitro using a lipophilic fluorescent dye as a model hydrophobic drug. Ca. 73% and 34% of the total dye loaded in the particles was found to be released at pH 5.0 and 7.4 in 24 h, respectively. The growth of human neuroblastoma cells was not affected by the incubation with the core-shell particles and their cleavage by-products up to 3 mg/ml concentration. The physicochemical and the functional features support the potential value of the acid-cleavable poly(BA) core-poly(PEG-A) shell particles as carriers for the delivery of hydrophobic drugs at acidic sites.     

Novel polymeric microspheres containing norcantharidin for chemoembolization.

Chemoembolization has been found to be a potentially effective method of treating certain types of cancer. It involves arterial embolization of a tumor, in combination with simultaneous or subsequent local delivery of chemotherapeutic agents. In this study, PLGA-alginate microspheres were evaluated for their potential application in chemoembolization. Norcantharidin, which possesses anti-tumor properties, was used to investigate the application of drug-containing microspheres for chemoembolization. The release profiles of alginate, PLGA and PLGA-alginate microspheres were markedly different in phosphate buffered saline, with the composite microspheres showing the most appropriate release rate for chemoembolization. Burst effect decreased while particle size increased with increasing proportion of alginate in the PLGA-alginate microspheres. PLGA-alginate microspheres containing norcantharidin were effective in destroying the cancer cells used in this study. The growth inhibitory effect was concentration and time dependent. These microspheres also exhibited excellent embolization and therapeutic effects on rats with transplanted tumors.     

Drug release characteristics of unimolecular polymeric micelles.

Biodegradable, unimolecular polymeric micelles possess several features that are attractive for drug delivery applications: Thermodynamic stability, ability to encapsulate and solubilize a hydrophobic guest molecule, biodegradability, as well as size and surface characteristics that prevent rapid clearance by the RES. Here we investigate the potential of these unimolecular polymeric micelles to release a drug for an extended time. Lidocaine was used as a model drug for in vitro studies using a horizontal diffusion cell and cellulose membrane that prevented polymer transport from the source to the receiver compartment. The transport of free lidocaine from source to receiver under sink conditions was zero-order and complete within 8 h. The transport of lidocaine initially encapsulated in polymer was zero-order for the first 14 h, and 96% of the lidocaine was detected within 24 h.     

Study on drug release behaviour of CDHA/chitosan nanocomposites--effect of CDHA nanoparticles.

To explore the effect of nanofiller-polymer interaction on the drug release behaviour from a monolithic membrane prepared by Ca-deficient hydroxyapatite (CDHA)/chitosan nanocomposite, release kinetics was investigated in terms of different synthetic processes, i.e. in situ and ex situ routes, and various amounts of CDHA. It was found that a higher value of diffusion exponent (n) was obtained for the membranes in situ synthesized compared with those ex situ prepared. In addition, the n value of the membranes in situ synthesized increased with increasing CDHA amount, which remained in the range below 10wt.%. However, as CDHA content exceeded 30%, the n value remained constant. It indicates that the drug diffusion mechanism is altered by the CDHA-chitosan interaction which is strongly influenced by both the synthesis process and the concentration of the CDHA nanofiller in the membrane. On the other hand, a lower permeability (P) value of the membranes was observed for those prepared via the in situ process. Furthermore, P value decreased and increased with increasing CDHA amount in the range below and above 10wt.%, respectively. It demonstrates that CDHA nanofillers act either diffusion barrier or diffusion enhancer for the CDHA/chitosan membranes, which is determined by the concentration of CDHA nanofiller and the synthesis route of nanocomposite.     

Silk microspheres for encapsulation and controlled release.

A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load protein drugs in active form for controlled release. The lipid was subsequently removed by methanol or sodium chloride treatments, resulting in silk microspheres consisting of beta-sheet structure and about 2 mum in diameter. NaCl treated microspheres had smoother surfaces compared to the methanol treatments based on SEM analysis, and both types of microspheres had a mixture of multilamellar and unilamellar structures. A model protein drug, horseradish peroxidase, was encapsulated in the microspheres. Freeze-thaw cycles during preparation led to higher loading of the peroxidase due to improved mixing between the silk and drug, while without this process the drug and silk remained in separate layers or domains in microspheres. This partitioning was determined with fluorescein-labeled silk and rhodamine-labeled dextran. Small molecules such as the enzyme substrate 3,3',5,5'-tetramethylbenzidine, Mw=240 Da, and its oxidized product freely diffused through the MeOH- and NaCl-processed silk microspheres so that enzyme loading and activity could be determined. Enzyme activity was retained during processing and in the final microspheres. The enzyme release profile depended on the NaCl-process used in microsphere preparation. The physically cross-linked beta-sheet structure of silk fibroin and the residual lipids in the microspheres played important roles in controlling enzyme release profiles. The silk microspheres have the potential for diverse applications where controlled protein release from biocompatible, mechanically tough, and slowly biodegradable carriers is desirable.     

Elevated temperature accelerated release testing of PLGA microspheres.

Drug release from four different poly(lactic-co-glycolic) acid (PLGA) microsphere formulations was evaluated under "real-time" (37 degrees C) and accelerated release testing conditions of elevated temperature (45, 53, 60 and 70 degrees C) and increase in flow rate (4-35 ml/min) using United States Pharmacopeia (USP) apparatus 4. Formulation 5 K (composed of low Mw PLGA) exhibited diffusion-controlled kinetics in "real-time". Whereas, formulations 25 K, 28 K and 70 K (composed of medium and high Mw PLGA) followed erosion-controlled kinetics at 37 degrees C. Temperature-induced degradation of the microspheres was studied by monitoring drug release rates, change in molecular weight and morphological changes. Drug release rates at elevated temperature were used to predict "real-time" release applying the Arrhenius equation. The energy of activation for dexamethasone release from PLGA microspheres was calculated as 19.14 kcal/mol. Molecular weight change measured by gel permeation chromatography followed first order kinetics for both "real-time" and accelerated release. All four formulations exhibited morphological changes (such as surface pore closing and geometry change) at elevated temperature with consequent reduction in burst release.     

Dual release of proteins from porous polymeric scaffolds.

To create porous scaffolds releasing in a controlled and independent fashion two different proteins, a novel approach based on protein-loaded polymeric coatings was evaluated. In this process, two water-in-oil emulsions are forced successively through a prefabricated scaffold to create coatings, containing each a different protein and having different release characteristics. In a first step, a simplified three-layered system was designed with model proteins (myoglobin and lysozyme). Poly(ether-ester) multiblock copolymers were chosen as polymer matrix, to allow the diffusion of proteins through the coatings. The model system showed the independent release of the two proteins. The myoglobin release was tailored from a burst to a linear release still on-going after 60 days, while the lysozyme release rate was kept constant. Macro-porous scaffolds, with a porosity of 59 vol.%, showed the same ability to control the release rate of the model proteins independently. The relation between the coatings properties and their release characteristics were investigated with the use of a mathematical diffusion model based on Fick's second law. It confirmed that the multiple coated scaffolds are biphasic system, where each coating controls the release of the protein that it contains. This approach could be of value for tissue engineering applications.     

Effect of protein molecular weight on release from micron-sized PLGA microspheres.

This study investigates the effect of protein molecular weight on release kinetics from polymeric microspheres (1-3 microm). Proteins were encapsulated at high and low loadings in poly(lactic-co-glycolic acid) (PLGA) by a phase inversion technique. Mechanism of release from this type of microsphere appeared to be dependent on protein molecular weight for microspheres with low loadings (0.5-1.6%), while independent of protein molecular weight for microspheres with high loadings (4.8-6.9%). At low loadings, release of larger proteins was dependent on diffusion through pores for the duration of the study, while smaller proteins seemed to depend on diffusion through pores initially and on degradation at later times. Following an initial diffusion phase from low loaded microspheres, lysozyme and carbonic anhydrase, the two smallest proteins, exhibited lag phases with curtailed protein release followed by a phase of increased protein release between 4 and 8 weeks, a phenomenon not evident for larger proteins. It appears that by 8 weeks, PLGA had degraded enough to allow additional release of smaller proteins which were entrapped efficiently within the microspheres. Higher loaded microspheres, which have more interconnecting channels, did not exhibit the pronounced shift from diffusion-based to polymer degradation-based release seen with the lower loaded microspheres. Interestingly, microspheres encapsulating large proteins maintained sustained release rates for 56 days.     

Novel sustained release microspheres for pulmonary drug delivery.

A novel process for generating sustained release (SR) particles for pulmonary drug delivery is described. High purity nanoparticles of a hydrophilic, ionised drug are entrapped within hydrophobic microspheres using a spray-drying approach. Sustained release of the model drug, terbutaline sulphate (TS), from the microspheres was found to be proportional to drug loading and phospholipid content. Microspheres with a 33% drug loading exhibited sustained release of 32.7% over 180 min in phosphate buffer. Release was not significantly different in simulated lung fluids. No significant burst release was observed which suggested that nanoparticles were coated effectively during spray-drying. The absence of nanoparticles at the microsphere surface was confirmed with confocal microscopy. The sustained release microspheres were formulated as a carrier-free dry powder for inhalation, and exhibited a favourable Fine Particle Fraction (FPF) of 46.5+/-1.8% and Mass Median Aerodynamic Diameter (MMAD) of 3.93+/-0.12 microm.     

Indomethacin release from ion-exchange microspheres: impregnation with alginate reduces release rate.

Ion-exchange microspheres (MS) designed as a drug delivery system for embolization coupling ability to occlude vessels and chemotherapy were used to evaluate a manufacturing process allowing to control the drug release rate through reduction of diffusion rate of the drug within the particle by impregnation of calcium alginate inside the porous MS. Impregnation was performed by diffusion of sodium alginate inside DEAE-Trisacryl(R) MS, dispersion of the MS in deionised water and gelling alginate by adding CaCl(2) to the dispersed MS. Studied parameters were alginate concentration, alginate diffusion time and calcium concentration. Indomethacin was loaded into the MS by eluting an aqueous indomethacin solution through a chromatographic column packed with impregnated MS. Indomethacin loading was reduced by alginate. Swelling studies showed indomethacin loading enhanced the hydrophobicity of MS while impregnation had no effect. This had an incidence on indomethacin release rate, which was assessed using the rapid elution of PBS through loaded impregnated MS packed in a column. Indomethacin loading reduced its own rate of release. MS impregnated with 2% w/v alginate gelled with a 40 mM calcium solution presented the lower release rate. This work indicated the manufacturing conditions to display a calcium alginate matrix effect on indomethacin release from DEAE-Trisacryl MS.     

Gentamicin extended release from an injectable polymeric implant.

Gentamicin sulfate, a potent antibiotic agent, is currently used for treatment of osteomyelitis mainly by intravenous injection with a long-term indwelling catheter, local implant of antibiotic containing polymethylmethacrylate beads or calcium phosphate (bone cements). Searching for more effective treatments, this study was designed to evaluate biodegradable injectable gelling polymeric devices for the controlled release of gentamicin sulfate in the treatment of invasive bacterial infections. Gentamicin sulfate was incorporated in poly(sebacic-co-ricinoleic-ester-anhydride P(SA-RA)) paste at 10-20% w/w and its release in buffer solution was monitored. The in vitro activity of the formulations was determined against Staphylococcus aureus. A constant release of active gentamicin for over 28 days was found. The stability of the formulation was determined under different storage conditions. The formulations were stable to sterilization by gamma-irradiation and long term storage under freezing. The toxicity of the polymer and the formulations with gentamicin was examined by subcutaneous injection to rats. Four weeks after implantation, histopathological examination of the tissues surrounding the implant showed no inflammation. A preliminary study revealed positive effect of gentamicin containing P(SA-RA) on established osteomyelitis in a rat model. In conclusion this study suggests that poly(sebacic-co-ricinoleic-ester-anhydride) 3:7 loaded with 10%-20% gentamicin sulfate, might be used as an injectable biodegradable device for in situ treatment of osteomyelitis induced by S. aureus.     

Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process.

Human serum albumin (HSA) was encapsulated as a model protein in microspheres of biodegradable and biocompatible polymers by the water-in-oil-in-water (w/o/w) emulsion solvent extraction/evaporation (double emulsion) technique for purpose of controlled release. To improve the properties and control the rate of drug release of the delivery vehicle, materials with different hydrophobicity from that of their conventional counterparts, such as poly(lactide-co-ethylene glycol) (PELA) in place of poly(lactide-co-glycolide) (PLGA) as the polymer matrix, ethyl acetate/acetone in place of dichloride methane (DCM) as the (co)solvent and d-alpha tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS) as the additive, were used to prepare the microspheres. It has been found that PELA microspheres, compared with PLGA ones, were slightly smaller in size if prepared at identical emulsification strength. They had more porous surface and internal structure, higher encapsulation efficiency (EE) and more rapid in vitro release rate. Furthermore, the physical properties of the microspheres were also affected by the presence of solvents and additives and their properties. Our results suggest that these materials could have interesting potential applications in preparation of polymeric microspheres for controlled protein release.     

Factors influencing the oligonucleotides release from O-W submicron cationic emulsions.

We recently described a positively charged O-W emulsion as a delivery system for oligonucleotides (ON) [Teixeira et al., Pharm. Res. 16 (1999) 30-36]. The present paper investigates the role of the main formulation parameters that may have an influence on the release-rate of a model ON in a protein-containing medium, i.e. the nature of the oily core, the presence of pegylated lipids, the lipid phase transition temperature, and the cationic lipid structure. The use of cationic lipids bearing diacyl chains (and especially polycations) appeared as the only efficient strategy to reduce the ON release rate. In order to have a better insight on the nature of the interactions between the ON and the interfacial lipids, adsorption isotherms at the air-water interface, fluorescence resonance energy transfer and zeta-potential measurements have been performed. Electrostatic interactions were found to play a crucial role. In contrast, the incorporation of PEG-phospholipids acted as a barrier and maintained the ON molecules distant from the interface, leading to a more rapid release. Finally, ON integrity was assessed by a competitive hybridization assay. The results suggest the existence of a transient ion-pair (ON-cationic lipids) protecting ON against nuclease degradation even after its release from the emulsions.     

Preparation, characterization and in vitro release of gentamicin from PHBV/wollastonite composite microspheres.

Composite microspheres have been prepared from bioactive wollastonite (W) and biodegradable poly (hydroxybutyrate-polyhydroxyvalerate) (PHBV) in the present study. Gentamicin was encapsulated into the microspheres by the absorption method and the in vitro release of the gentamicin from the microspheres was performed in distilled water, modified simulated body fluid (SBF) and phosphate buffered saline (PBS) at 37 degrees C for 22 days, respectively. The results showed that the release behavior of gentamicin from PHBV/W composite microspheres was similar to that from the pure PHBV microspheres when the experiment was performed in distilled water. However, in the PBS and SBF solutions, gentamicin released from the PHBV/W composite microspheres at a relatively lower rate as compared to that of the pure PHBV microspheres and 90% of the total amount of gentamicin released from the composite microspheres after soaking for 22 days, which was much longer than that for the release of the same amount gentamicin from the pure PHBV microspheres (8 days). Scanning electron microscopy (SEM) and energy-dispersive spectrometer (EDS) analysis on the microspheres after release in SBF and PBS revealed that a microporous apatite layer was formed on the composite microspheres surface, which resulted in a controlled release behavior of the gentamicin from the PHBV/W composite microspheres. All of these results provided the possibility that the PHBV/W composite microspheres could be applied as alternative drug controlled release systems, especially as bone fillings for bone repair due to their advantages of controlled releasing antibiotics and apatite-formation ability, through which the implanted microspheres could chemically bond to the surrounding tissue in vivo.     

聚乳酸乙醇酸/ RNA Ⅲ抑制肽缓释微球组织相容性评价

目的:在前期实验证实可防治葡萄球菌感染的RNA Ⅲ抑制肽(RNAⅢ inhibiting peptide, RIP)具有良好的组织相容性和安全性的基础上,进一步评价聚乳酸乙醇酸/ RIP(PLGA/ RIP)缓释微球的组织相容性.方法: 实验于2005-10/2007-10在解放军总医院骨科研究所、临床药理研究所及医学动物实验中心完成.①PLGA/RIP微球制备:采用Fmoc法由C端至N端先合成粗品肽;采用反相液相色谱法对RIP粗品进行纯化分析,按紫外吸收峰收集组分,冷冻干燥,得到RIP纯品.再采用液相复乳法制备直径50～70 μm的PLGA/RIP微球.②组织相容性实验:以急性全身毒性实验观察 PLGA/RIP的全身毒性反应;MTT细胞毒性实验观察PLGA/RIP对细胞增殖的影响;肌肉内植入实验观察材料有无肌肉刺激反应;过敏实验观察PLGA/RIP的致敏情况;热原实验观察材料对体温的影响.结果:①急性全身毒性实验结果:腹腔注射PLGA/RIP洗提原液和50%的PLGA/RIP洗提液后动物无中毒反应,无死亡,体质量无明显变化.②MTT细胞毒性实验结果:两种洗提液的平均细胞增殖率均大于85%,细胞毒等级1级,不具有细胞毒性.③肌肉内植入实验结果:RIP和PLGA/RIP植入4 周后,组织未见明显充血、变性或坏死.材料周围未见明显炎症细胞浸润, 材料已被纤维囊包裹.④过敏实验结果:3组动物的平均原发刺激指数分别为0.38,0.33和0.31,3组间无显著差别.⑤热原实验结果:各组动物体温升高均在0.5 ℃以下, 证实材料无热源性,符合热原实验的评价标准.结论: PLGA/RIP不引起全身毒性反应,无细胞毒性,未见免疫排斥,不引起过敏反应,无热源性,具有良好的组织相容性和安全性.